MVASI
MVASI is a vascular endothelial growth factor inhibitor used to treat several types of advanced, metastatic, or recurrent cancers, including colorectal, lung, glioblastoma, renal, cervical, and ovarian malignancies. It is primarily administered in combination with specific chemotherapy regimens or interferon-alfa, though it may be used as a single agent in certain maintenance or recurrent settings. The drug is indicated for various stages of treatment, such as first-line or second-line therapy, but is specifically not indicated for the adjuvant treatment of colon cancer.
How MVASI Works
MVASI works by binding to vascular endothelial growth factor (VEGF) to prevent it from interacting with its receptors on the surface of endothelial cells. This interaction normally stimulates the proliferation of endothelial cells and the formation of new blood vessels, a process known as angiogenesis. By blocking this pathway, the drug reduces microvascular growth and inhibits the progression of metastatic disease.
Details
- Status
- Prescription
- First Approved
- 2017-09-14
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
MVASI Approval History
What MVASI Treats
8 indicationsMVASI is approved for 8 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Metastatic Colorectal Cancer
- Non-Small Cell Lung Cancer
- Glioblastoma
- Renal Cell Carcinoma
- Cervical Cancer
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer
MVASI Target & Pathway
ProTarget
A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Tumors need blood supply to grow, so they secrete VEGF to create new vessels. Blocking VEGF starves tumors of oxygen and nutrients, inhibiting their growth.
Pathway Context
VEGF binds to VEGFR on blood vessel cells to stimulate new vessel formation
Receptors on blood vessel cells that respond to VEGF signals to form new blood vessels. Cancer cells exploit this pathway to ensure blood supply for tumor growth. Blocking VEGFRs prevents tumor angiogenesis and limits cancer progression.
MVASI is a lower-cost alternative to Avastin with no clinically meaningful differences. Requires prescriber approval to substitute.
MVASI Competitors
Pro5 other drugs also target VEGF. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (VEGF). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to MVASI
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
MVASI FDA Label Details
ProIndications & Usage
FDA Label (PDF)MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. Unresectable, locally advanced, recurrent or metastat...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.